Business Context and Reporting Period
This Form 8-K, filed on February 7, 2022, reports events occurring on February 4, 2022, for Second Sight Medical Products, Inc. (the "Company"). The filing announces the entry into a definitive Merger Agreement with Nano Precision Medical, Inc. ("NPM"). Upon consummation, NPM will merge into a wholly-owned subsidiary of the Company, and NPM will become a wholly-owned subsidiary. The Company intends to change its name and trading symbol following shareholder approval.
Key Financial Metrics and Transaction Terms
This filing details a corporate transaction rather than periodic financial performance. Consequently, standard metrics such as revenue, profit, cash flow, and operating margins are not reported in this document.
- Consideration: NPM shareholders will receive approximately 134,349,464 shares of the Company's common stock ("Merger Shares").
- Ownership Structure: The Merger Shares will represent approximately 77.32% of the Company's total issued and outstanding shares on a fully converted basis.
- Financing Advance: The Company agreed to provide an $8 million investment advance to NPM via a SAFE agreement pending the closing of the Merger.
- Termination Fees:
- $1 million payable by the Company to NPM if terminated due to the Company's cash balance falling below $64 million.
- $5 million payable by the Company to NPM if terminated due to an adverse change in the Company's Board recommendation or a competing acquisition.
- $5 million payable by NPM to the Company if terminated due to NPM entering a competing acquisition.
Material Changes and Governance
The primary material change is the proposed reverse merger structure where NPM shareholders will hold a controlling interest (77.32%) in the combined entity. Post-closing governance is anticipated to include a five-member Board of Directors: Adam Mendelsohn, Aaron Mendelsohn, Dean Baker, Gregg Williams, and Alexandra Larson. Adam Mendelsohn is expected to serve as CEO, and Brigid Makes as CFO. Three current Company directors (Gregg Williams, Aaron Mendelsohn, and Dean Baker) also serve on NPM's board and hold substantial financial interests in NPM.
Guidance, Risks, and Contingencies
The transaction is subject to several material conditions, including shareholder approval from both companies, the effectiveness of a Form S-4 registration statement, and the absence of a material adverse effect. The Merger Agreement includes a termination date of June 30, 2022, extendable to September 30, 2022.
Risks and Contingencies:
- Shareholder Approval: Failure of either Company's or NPM's shareholders to approve the transaction will result in termination.
- Integration Risks: Potential disruption to operations, diversion of management attention, and challenges in integrating businesses.
- Market Conditions: Risks related to the COVID-19 pandemic, economic conditions, inflation, and interest rate changes.
- Forward-Looking Statements: The filing contains forward-looking statements regarding the future business and financial performance of the combined company, which are subject to inherent uncertainties.
Investor Verification Checklist
- Verify the final terms of the Merger Agreement and the specific exchange ratio in the upcoming Form S-4 proxy statement.
- Confirm the Company's cash position relative to the $64 million threshold that triggers a $1 million termination fee.
- Review the financial statements of NPM to assess the valuation implied by the 77.32% ownership stake.
- Monitor the status of the Form S-4 filing and the scheduled shareholder votes for both entities.
- Assess the potential dilution impact on existing Company shareholders resulting from the issuance of approximately 134.3 million new shares.